(Circulation. 2001;104:876.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
HPA-2 Met/VNTR B Haplotype as a Genetic Predictor of Myocardial Infarction and Sudden Cardiac Death
From the Medical School, University of Tampere and Tampere University Hospital, Tampere (J.M., P.J.K.), and the Department of Forensic Medicine, University of Helsinki, Helsinki (A.P.), Finland; and UCLA Department of Human Genetics, Los Angeles, Calif (M.P.).
Correspondence to Dr Jussi Mikkelsson, University of Tampere, Medical School, B Building, FIN-33014 Tampere, Finland. E-mail jm56215{at}uta.fi
| Abstract |
|---|
|
|
|---|
have been studied previously in hospitalized patients with acute coronary syndromes. The significance of these polymorphisms in victims of sudden cardiac death is not known. Methods and Results The association of these 2 polymorphisms with coronary atherosclerosis, coronary artery stenosis, coronary thrombosis, myocardial infarction (MI), and SCD was studied in the Helsinki Sudden Death Study, which comprised 2 large autopsy series, collected 10 years apart during 1981 to 1982 and 1991 to 1992, of 700 middle-aged white Finnish men who suffered sudden or violent out-of-hospital death. The 2 polymorphisms showed an almost complete linkage disequilibrium. Men with acute MI (n=80) and coronary thrombosis (n=65) were more likely to be carriers of the HPA-2 Met allele (OR 2.0 and 2.6, respectively, P<0.005 for both) than were control subjects who died of noncardiac causes (n=367). In men <55 years old, the Met allele was overrepresented (OR 2.2) among victims of SCD (n=98) compared with control subjects (n=249). In men <55 years old, 17 of 29 men with acute MI (58.6%) and 16 of 23 men with coronary thrombosis (69.6%) were carriers of the HPA-2 Met allele compared with the 49 of 249 (19.7%) who had died of noncardiac causes (ORs 5.6 and 9.2, respectively). Similar associations were observed in the separate analyses of both autopsy series.
Conclusions Our results suggest that the HPA-2 Met/VNTR B haplotype of the platelet von Willebrand factor and thrombin receptor protein GP Ib-V-IX may be considered to be a major risk factor of coronary thrombosis, fatal MI, and SCD in early middle age.
Key Words: genetics myocardial infarction platelets risk factors thrombosis
| Introduction |
|---|
|
|
|---|
Erosion or disruption of the fibrous cap of an atheromatous plaque, subsequent platelet adhesion, aggregation, and thrombus formation are main events in the development of acute myocardial infarction (AMI) and SCD in patients with CHD.6,7 The primary event after rupture or fissuring of coronary plaques, eventually resulting in platelet aggregation and thrombus formation, is the activation of platelet GP Ib-IX-V receptors by high shear stress and/or thrombin and the subsequent receptor binding to subendothelial collagen via von Willebrand factor.8
The altered amino acid sequence (C to T nucleotide substitution resulting in Thr to Met transition) responsible for the HPA-2 polymorphism is located in the leucine-rich region responsible for the ligand binding of GP Ib.9 The HPA-2 polymorphism is in nearly complete linkage disequilibrium with a size polymorphism in the same gene. The Met allele of the HPA-2 polymorphism is associated with 3 B and 4 A tandem repeats of the size polymorphism.10,11 All individuals with the Met allele have been reported to carry the B allele, but 1% to 5% of B allele carriers are Thr homozygotes. Thus, any association of the Met allele with CHD may also be due to an effect of the VNTR polymorphism on platelet function.
Thus far, HPA-2 polymorphism of the gene for GP Ib
has not been found to affect the receptor binding to von Willebrand factor,12,13 but in a study using agonist-induced aggregation under high shear, the B allele carriers of the VNTR polymorphism (Met carriers of the HPA-2 polymorphism) had increased platelet activity, even though the study population was on aspirin.14 Previous studies on CHD patients1517 have not unanimously supported an association between the Met allele and CHD. Only 2 studies, however, focused on acute coronary events, but they have reported controversial results.18,19 The HPA-2 polymorphism has been found to be associated with ischemic cerebrovascular disease20 and ischemic stroke.21
In the present study, we investigated the association of the GP Ib
HPA-2 and VNTR polymorphisms with coronary atherosclerosis and the degree of coronary stenosis, coronary thrombosis, MI, and SCD in 2 large autopsy series of sudden, out-of-hospital deaths.
| Methods |
|---|
|
|
|---|
|
Characteristics and Phenotypes of MI
The presence of MI in the series was confirmed by macroscopic and histological examination of the myocardium. The presence/absence of neutrophil granulocytes was considered diagnostic of an AMI and the presence/absence of fibrous scar tissue diagnostic of an old MI. On the basis of the autopsy findings and nitro blue tetrazolium staining, the MI was classified as either transmural or nontransmural. Of the entire series of 700 men, 184 were found to have had MI. Eighty-five men had died of AMI with or without an old MI. Of the AMI cases, 39 were associated with coronary thrombosis, of which 24 were acute. Old nonfatal MI scar without AMI was found in an additional 99 cases, of which a macroscopic organizing thrombus was observed in 14 cases. AMI was transmural in 52% of men <55 years old (n=29) and in 42% of men >55 years old (n=55). Macroscopic coronary thrombosis was found in 89.5% of cases with transmural AMI, whereas the corresponding figure in nontransmural AMI was only 11%.
Measuring the Percentage of Stenosis in Silicone Rubber Casts of the Coronary Arteries
At autopsy, coronary angiography was performed, with vulcanizing liquid silicone rubber mixed with lead oxide used as the contrast medium. The proximal, middle, and distal stenoses of the main trunks of the 3 main epicardial coronary arteries (left anterior descending, left circumflex, and right coronary arteries) were measured from the rubber cast model. The percentage of the stenosis was obtained by dividing the diameter (millimeters) of the greatest stenosis by the diameter of the nearest proximal undamaged part of the cast model of the artery, resulting in 9 measurements of the degree of stenosis for each individual. These measurements were available in 670 men.
Measuring the Area of Atherosclerosis by Morphometry of Coronary Arteries
The coronary arteries were fixed in 10% buffered formalin and stained for fat by the Sudan IV staining method. The following atherosclerotic changes were evaluated for all arteries: fatty streaks, elevated plaques, and complicated lesions. The proportional area of each particular atherosclerotic change in the most affected coronary artery was used for statistical analyses. Data on the atherosclerotic changes of coronary arteries were available in 512 men from both series.
DNA Extraction, HPA-2, and VNTR Genotyping
In the 1981 to 1982 series, DNA was extracted from paraffin-embedded samples of cardiac muscle, and in the 1991 to 1992 series, DNA was isolated from frozen (-70°C) cardiac muscle samples.22 Genotyping for the HPA-2 polymorphism was performed with restriction enzyme analysis with slight modifications from Kekomaki et al23 and VNTR polymorphism just as described previously by Kekomaki et al. Genotyping was successful for both polymorphisms in 626 cases (HPA-2 630 and VNTR 643).
Risk Factors for Coronary Artery Disease and Sudden Death
A spouse, relative, or close friend of the deceased could be interviewed in 500 cases (71.4%). Questions delineated past and recent smoking and drinking habits as well as previous illnesses. On the basis of these interviews, men were classified as smokers (n=353) or nonsmokers (n=88). Ex-smokers (n=67) were included in the class of smokers for statistical analysis. Average daily alcohol consumption of the deceased was calculated from information given by the interviewed persons. Questions on previous illnesses showed that 107 men had suffered from hypertension and 113 from diabetes. The validity of the risk factor data and their collection method have been discussed previously.24
Statistical Analysis
Characteristic differences between causes of deaths were analyzed bivariately with Students t tests. Analyses of the effect of genotype on MI with/without thrombosis and comparisons between acute thrombosis cases and other SCD victims were based on logistic regression with the risk factor data. We also analyzed for the interaction between genotypes and age groups and groups of causes of deaths using logistic regression. Analyses of atherosclerotic variables and stenosis percentage are based on ANOVA/MANOVA with Bonferroni adjustments. All data analyses were performed both with and without the interview data. The computation was carried out with STATISTICA/WIN (version 5.0, Statsoft Inc) and SPSS for Windows (version 10.0, SPSS).
| Results |
|---|
|
|
|---|
|
SCD and HPA-2 Polymorphism
The frequency of the HPA-2 Met allele was similar among cases of SCD, violent deaths, and deaths due to other diseases (P>0.3). Men with the Met genotype, however, were more frequently (OR 2.2; 95% CI 1.3 to 3.7, P<0.001 for age grouphaplotype interaction) found among young (<55 years old) victims of SCD (n=98) compared with those (n=249) who died of noncardiac causes without significant coronary disease or MI at autopsy (referred to as controls later in this section) (34.7% versus 19.7%). Genotype distribution is given in Tables 3 and 4.
|
|
Coronary Thrombosis, MI, and the HPA-2 Polymorphism
The frequency of the HPA-2 Met allele carriers among men with AMI (n=80) was higher (OR 2.0; 95% CI 1.1 to 3.7, P<0.005) than in controls (n=367) (26.2% versus 21.3%), and the HPA-2 Met allele was found more often (OR 2.6; 95% CI 1.3 to 5.3, P<0.005) among men with coronary thrombosis (n=65) (36.9%) than in controls (adjusted analyses).
Age group (<55 versus >55 years old) showed a significant interaction with the HPA-2 polymorphism on AMI and coronary thrombosis (P<0.001 for all). In men <55 years old, 69.6% of the 23 men with coronary thrombosis had the HPA-2 Met allele, compared with 19.7% in 249 controls (OR 9.2; 95% CI 2.4 to 35.0). This allele was found in 58.6% of the 29 men with AMI (OR 5.6; 95% CI 1.8 to 17.3, compared with controls) (Tables 3 and 4). The HPA-2 Met allele was found more frequently in individuals with SCD due to an acute coronary/myocardial lesion in men <55 years old compared with men with SCD due to CHD but without an acute lesion, men with SCD not due to CHD, and controls (ORs 3.5, 8.8, and 5.4; P<0.005, P<0.01, and P<0.005, respectively). No statistically significant differences were observed between the 3 latter groups (data not shown) (Table 5).
|
In men <55 years old in the 1981 to 1982 series, 77.0% of men with AMI carried the HPA-2 Met allele, and it was found in 66.7% of men with coronary thrombosis compared with 19.6% among controls. In the 1991 to 1992 series, the respective frequencies in men <55 years old were 43.8% for men with AMI, 75.0% for men with coronary thrombosis, and 19.7% for controls. These differences were independently significant in both series (analysis not shown). The above associations were significant both in men with risk factor data and in those who lacked these data.
Coronary Disease and HPA-2 Polymorphism
The degree of coronary stenosis as well as the areas of atherosclerotic lesions failed to show an association with the HPA-2 Met allele in the entire series. Age group (<55 versus >55 years), however, showed a significant interaction with the HPA-2 polymorphism, with effect on coronary stenosis (5p<0.005) and elevated coronary lesions (5p=0.05). In men <55 years old, the average degree of coronary stenosis was significantly more severe and the average vessel wall area covered by elevated lesions larger in Met allele carriers than in noncarriers. In addition, the cause of death interacted with genotype and age group (P<0.05), showing in post hoc analysis that the difference in coronary stenosis was most pronounced among young (<55 years old) victims of SCD with the Met allele compared with the low-MI-risk genotype (Table 3). This may be because CHD was the cause of SCD in this age group in 85% of the carriers of the Met allele but in only 60% of the carriers of the low-MI-risk genotype, of whom more individuals had died of cardiomyopathy or other cardiac causes and showed only mild atherosclerosis at the autopsy.
| Discussion |
|---|
|
|
|---|
was associated with coronary thrombosis, AMI, and SCD in early middle age. The association of this haplotype with elevated coronary lesions and severe vessel stenosis among young SCD victims is likely to result from increased platelet adhesion and organization on coronary lesions. These results could be confirmed in both the 1981 to 1982 and 1991 to 1992 autopsy series in their separate, independent analyses. These findings suggest that the HPA-2 Met/VNTR B haplotype of GP Ib
may be a predictor of fatal complications of atherosclerosis in early middle age. Because of an almost complete linkage between the 2 polymorphisms, this may be due to an effect of one or both of these variants on platelet function or this may serve as a surrogate (linkage) marker for an as yet unknown factor associated with platelet function. The role of genetic factors is considered to be very important in SCD and first MI; positive family history is an independent risk factor for primary cardiac arrest and sudden death.4,5 Our study population with relatively young Finnish men with fatal MI and SCD represents individuals with high environmental6 and familial4,5 risk for coronary events. The Finnish population is also ethnically and culturally very homogenous and thus particularly suitable for genetic association studies.25
Possible explanations for differences in the results of association studies on MI include the fact that younger men more often suffer Q-wave infarctions. Transmural (often Q-wave) infarction is nearly always caused by an occluding fibrin-rich (red) coronary thrombus, whereas in most patients (75% to 80%) with unstable angina pectoris who develop nontransmural (usually nonQ-wave) infarction, occluding thrombi are absent and the thrombotic material present (in
50% of the cases) is usually composed of platelets (white thrombus) adhered to preexisting stenotic lesions.2628 Thus, cases of Q-wave infarction (younger men) may represent individuals in whom prothrombotic factors are more important than in older victims of nonQ-wave MI. It is also possible that factors related to platelet aggregation may be more important in Q-wave than in nonQ-wave infarction,22,28 whereas factors related to platelet adhesion may be important in both types of infarction. This is probably due to the importance of the glycoprotein receptors mediating platelet adhesion as the primary event of the clot formation after fissures/erosion of the coronary lesion surface. The subsequent evolution of this clot to vessel occlusion may be more dependent on other systemic/inherited factors affecting the activation of the coagulation cascade, thrombin generation, and binding of fibrinogen to platelets, which lead to the formation of the fibrin-rich (red) thrombus. Our current knowledge about the interplay between different platelet adhesion molecules is in a state of constant evolution, and the relative importance of individual elements in the time course of an evolving acute coronary event has not yet been sufficiently elucidated. We hope that the present findings may add a little piece to this puzzle.
Previous studies on the association of the HPA-2 polymorphism with coronary events18,19 have shown controversial results. Gonzalez-Conejero et al18 studied middle-aged individuals with various kinds of acute coronary events (Q-wave MI, nonQ-wave MI, and unstable angina pectoris) and found the Met allele/B allele of the VNTR polymorphism to be associated with an increased risk of these events, whereas Ardissino et al19 studied very young patients with Q-wave MI and could not find an association between the Met allele and Q-wave MI. These results imply that the HPA-2/VNTR polymorphisms could be more strongly associated with nonQ-wave MI, in which platelet adhesion, more than aggregation, is thought to be the main pathogenetic event. Both of these previous studies, however, are based on event survivors and thus contain a selection bias, if one assumes that a risk factor could affect case fatality, which is an important issue when studying factors that may be associated with an increased risk of SCD.
We conclude that the HPA-2 Met/VNTR B haplotype of GP Ib
is strongly associated with SCD due to coronary thrombosis and fatal AMI in early middle age and may thus serve as a useful marker for inherited risk of MI/SCD in individuals with a familial burden of premature coronary mortality.
| Acknowledgments |
|---|
Received March 23, 2001; revision received June 7, 2001; accepted June 21, 2001.
| References |
|---|
|
|
|---|
2.
Gillum RF. Sudden coronary death in the United States: 198085. Circulation. 1989; 79: 756765.
3.
Norris RM. The natural history of acute myocardial infarction. Heart. 2000; 83: 726730.
4.
Escobedo LG, Zack MM. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation. 1996; 93: 20332036.
5.
Wannamethee G, Shaper AG, Macfarlane PW, et al. Risk factors for sudden cardiac death in middle-aged British men. Circulation. 1995; 91: 17491756.
6.
Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336: 12761282.
7. Badimon JJ, Fuster V, Chesebro JH, et al. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993; 87 (suppl II): II-3II-16.
8.
Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood. 1999; 94: 172178.
9.
Shen Y, Romo GM, Dong J-F, et al. Requirement of leucine-rich repeats of glycoprotein (GP) Ibalpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. Blood. 2000; 95: 903910.
10.
Kaski S, Kekomaki R, Partanen J. Systematic screening for genetic polymorphism in human platelet glycoprotein Ib
. Immunogenetics. 1996; 44: 170176.[Medline]
[Order article via Infotrieve]
11. Corral J, Gonzalez-Conejero R, Lozano ML, et al. New alleles of the platelet glycoprotein Ibalpha gene. Br J Haematol. 1998; 103: 9971003.[Medline] [Order article via Infotrieve]
12.
Li CQ, Garner SF, Davies J, et al. Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbalpha express HPA-2 epitopes and show equal binding of von Willebrand factor. Blood. 2000; 95: 205211.
13. Mazzucato M, Pradella P, De Angelis V, et al. Frequency and functional relevance of genetic threonine 145/methionine 145 dimorphism in platelet glycoprotein Ibalpha in an Italian population. Transfusion. 1996; 36: 891894.[Medline] [Order article via Infotrieve]
14. Douglas H, Gorog D, Ahmed N, et al. Functional significance of GP1b alpha receptor polymorphism in patients with coronary artery disease. Eur Heart J. 2000; 21 (suppl): 66.
15.
Murata M, Matsubara Y, Kawano K, et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation. 1997; 96: 32813286.
16. Sperr WR, Huber K, Roden M, et al. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res. 1998; 90: 117123.[Medline] [Order article via Infotrieve]
17. Ito T, Ishida F, Shimodaira S, et al. Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int J Hematol. 1999; 70: 4751.[Medline] [Order article via Infotrieve]
18.
Gonzalez-Conejero R, Lozano ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Ib alpha associated with arterial thrombotic disease. Blood. 1998; 92: 27712776.
19.
Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood. 1999; 94: 4651.
20.
Sonoda A, Murata M, Ito D, et al. Association between platelet glycoprotein Ib
genotype and ischemic cerebrovascular disease. Stroke. 2000; 31: 493497.
21.
Reiner AP, Kumar PN, Schwartz SM, et al. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke. 2000; 31: 16281633.
22.
Mikkelsson J, Perola M, Laippala P, et al. Glycoprotein IIIa PlA1/A2 polymorphism and sudden cardiac death. J Am Coll Cardiol. 2000; 36: 13171323.
23. Kekomaki S, Partanen J, Kekomaki R. Platelet alloantigens HPA-1, -2, -3, -5 and -6 in Finns. Transfus Med. 1995; 5: 193198.[Medline] [Order article via Infotrieve]
24. Mikkelsson J, Perola M, Penttila A, et al. The GPIIIa (ß3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis. 2001; 54: 721727.
25. Risch NJ. Searching for genetic determinants in the new millennium. Nature. 2000; 405: 847856.[Medline] [Order article via Infotrieve]
26. Freifeld AG, Schuster EH, Bulkley BH. Nontransmural versus transmural myocardial infarction: a morphologic study. Am J Med. 1983; 75: 423432.[Medline] [Order article via Infotrieve]
27. Keen WD, Savage MP, Fischman DL, et al. Comparison of coronary angiographic findings during the first six hours of non-Q-wave and Q-wave myocardial infarction. Am J Cardiol. 1994; 74: 324328.[Medline] [Order article via Infotrieve]
28. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992; 326: 287291.[Abstract]
This article has been cited by other articles:
![]() |
J. P. Corsetti, D. Ryan, A. J. Moss, D. L. Rainwater, W. Zareba, and C. E. Sparks Glycoprotein Ib{alpha} Polymorphism T145M, Elevated Lipoprotein-Associated Phospholipase A2, and Hypertriglyceridemia Predict Risk for Recurrent Coronary Events in Diabetic Postinfarction Patients Diabetes, May 1, 2007; 56(5): 1429 - 1435. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Karhunen, H. Forss, S. Goebeler, H. Huhtala, E. Ilveskoski, O. Kajander, J. Mikkelsson, A. Penttila, M. Perola, H. Ranta, et al. Radiographic Assessment of Dental Health in Middle-aged Men Following Sudden Cardiac Death Journal of Dental Research, January 1, 2006; 85(1): 89 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Feinbloom and K. A. Bauer Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2043 - 2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mikkelsson, M. Perola, and P. J. Karhunen Genetics of Platelet Glycoprotein Receptors: Risk of Thrombotic Events and Pharmacogenetic Implications Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 113 - 125. [Abstract] [PDF] |
||||
![]() |
E. V. Potapov, S. Ignatenko, B. A. Nasseri, M. Loebe, C. Harke, M. Bettmann, A. Doller, V. Regitz-Zagrosek, and R. Hetzer Clinical significance of PlA polymorphism of platelet GP IIb/IIIa receptors during long-term VAD support Ann. Thorac. Surg., March 1, 2004; 77(3): 869 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Snapir, J. Mikkelsson, M. Perola, A. Penttila, M. Scheinin, and P. J. Karhunen Variation in the alpha2B-adrenoceptorgene as a risk factor for prehospitalfatal myocardial infarction and sudden cardiac death J. Am. Coll. Cardiol., January 15, 2003; 41(2): 190 - 194. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |